Author: admin

“Celiac Disease Market”

(Albany, USA) DelveInsight’s “Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Celiac Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Celiac Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Celiac Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Celiac Disease market.

To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market Forecast

Some of the key facts of the Celiac Disease Market Report:

• The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease.
• In March 2025, Barinthus Biotherapeutics plc (NASDAQ: BRNS) has entered 2025 with a renewed strategic focus on immunological and inflammatory diseases. Following its restructuring, the company is well-positioned to advance its lead asset, VTP-1000, along with the SNAP-TI platform, for the treatment of celiac disease. With innovative design features that enhance antigen targeting, allow intramuscular administration, and potentially improve tolerability, VTP-1000 has the potential to become a leading therapy for the approximately 80 million people worldwide affected by celiac disease.
• In February 2025, PhaseV, a leader in software and machine learning (ML) for clinical trial optimization, announced a strategic partnership with Alimentiv Inc., a global gastrointestinal (GI) contract research organization (CRO). This collaboration aims to enhance the design and execution of advanced adaptive clinical trials for various GI conditions, including inflammatory bowel disease (IBD), celiac disease, eosinophilic gastrointestinal disease (EGID), and other related disorders.
• In October 2024, Topas Therapeutics reported positive topline results from its Phase IIa trial of TPM502 in celiac disease patients. The findings provide the first clinical proof of concept for the company’s proprietary nanoparticle platform, highlighting its potential to induce targeted, antigen-specific tolerogenic effects.
• In September 2024, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that direct T cells to manage diseases, has commenced its first-in-human Phase 1 trial of VTP-1000 in adults with celiac disease. This randomized, placebo-controlled study, incorporating a controlled gluten challenge, aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-1000.
• In May 2024, Entero Therapeutics, Inc. (previously known as First Wave BioPharma, Inc.) has introduced its new corporate identity and website. This rebranding comes after its recent merger with ImmunogenX and underscores the company’s commitment to tackling unmet needs in gastrointestinal health, including celiac disease, a condition that currently lacks approved treatments.
• In 2023, the United States represented the largest portion of the celiac disease market among the 7MM, contributing roughly 70% to the overall market.
• Among the EU4 and the UK, Italy had the highest market valuation for celiac disease, estimated at around USD 200 million.
• At present, a gluten-free diet is the sole effective treatment for celiac disease, with the market in Japan valued at around USD 1,500 million in 2023.
• Celiac disease exhibits a significant gender imbalance, primarily affecting females. In Germany, for example, around 60% of diagnosed cases are female.
• In 2023, classical celiac disease accounted for approximately 30% of all celiac disease cases in Japan.
• According to the Beyond Celiac foundation (2024), approximately 1 in 133 Americans, or around 1% of the population, has celiac disease. It is also estimated that up to 83% of Americans with celiac disease remain undiagnosed or are incorrectly diagnosed with other medical conditions.
• According to Stahl et al. (2023), Celiac disease is a prevalent chronic condition globally, with an aggregated prevalence of 1.4%, though it can be significantly higher in specific regions. In a prospective birth cohort study involving infants at risk for celiac disease in Europe and the United States, the incidence was estimated to be 3% in Sweden and 2.4% in Colorado.
• According to the Celiac Disease Foundation, celiac disease is a significant autoimmune disorder estimated to impact 1 in 100 people globally. Additionally, 2.5 million Americans remain undiagnosed and are susceptible to potential long-term health issues.
• Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
• Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
• The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males
• The Celiac Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.

Celiac Disease Overview

Celiac Disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. Celiac Disease causes an immune response that damages the lining of the small intestine, leading to malabsorption of essential nutrients. Celiac Disease affects both children and adults and can present with a wide range of gastrointestinal and non-gastrointestinal symptoms.

Celiac Disease symptoms commonly include abdominal pain, bloating, diarrhea, constipation, fatigue, weight loss, and nutrient deficiencies. Celiac Disease may also manifest through skin rashes, neurological issues, anemia, osteoporosis, and infertility in some individuals. Celiac Disease is strongly associated with genetic factors, particularly the HLA-DQ2 and HLA-DQ8 genes.

Celiac Disease diagnosis involves a combination of serologic testing for specific antibodies and confirmation through a small intestinal biopsy. Celiac Disease management requires a strict lifelong gluten-free diet, which helps in healing the intestinal lining and preventing further complications. Celiac Disease patients must avoid even trace amounts of gluten to maintain health and prevent flare-ups.

Celiac Disease awareness and early detection are crucial to preventing long-term health consequences. Celiac Disease research continues to explore potential therapies beyond dietary management, including enzyme treatments and immune-modulating agents to improve patient outcomes.

Get a Free sample for the Celiac Disease Market Report: https://www.delveinsight.com/sample-request/celiac-disease-cd-market

Celiac Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Celiac Disease Epidemiology Segmentation:

The Celiac Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Population of Celiac Disease in the 7MM
• Total Diagnosed Prevalent Population of Celiac Disease in the 7MM
• Type-specific Prevalent Population of Celiac Disease in the 7MM
• Gender-specific Prevalent Population of Celiac Disease in the 7MM
• Age-specific Distribution of Celiac Disease in the 7MM

Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Prevalence

Celiac Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Celiac Disease Therapies and Key Companies

• PRV-015 : Sanofi (Provention Bio)
• TAK-227/ZED1227: Zedira, Dr. Falk Pharma, and Takeda
• Latiglutenase(IMGX003): ImmunoGenX
• Ordesekimab: Provention Bio/Sanofi
• TAK-101 and Zamaglutenase: Takeda
• TPM502: Topas Therapeutics GmbH
• Ritlecitinib: Pfizer
• TAK-062: Takeda
• larazotide acetate: 9 Meters Biopharma, Inc.
• CCX282-B: ChemoCentryx
• BL-7010: BioLineRx, Ltd.

Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment Market

Celiac Disease Market Strengths

• The pipeline activity of Celiac Disease is quite efficient with the presence of variable key players such as First Wave BioPharma, Sanofi, Takeda, etc., which are efficiently involved in developing milestone treatment options.
• Latiglutenase has the potential to be a first to-market treatment for celiac disease, a GIdisorder that impacts approximately three million people in the US and for which no approved pharmacologic treatment currently exists.

Celiac Disease Market Opportunities

• Several organizations such as Celiac Disease Foundation, National Celiac Association (NCA), American Celiac Disease Alliance (Celiac Disease A), Coelic UK etc. are actively working to provide information and awareness of the disorder.
• There is ongoing research into celiac disease, including potential treatments and therapies. Individuals with celiac disease can contribute to this research by participating in clinical trials or fundraising for research organizations.

Scope of the Celiac Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Celiac Disease Companies: Sanofi (Provention Bio), Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
• Key Celiac Disease Therapies: PRV-015, TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Celiac Disease Unmet Needs, KOL’s views, Analyst’s views, Celiac Disease Market Access and Reimbursement

To know more about Celiac Disease companies working in the treatment market, visit @ Celiac Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Celiac Disease Market Report Introduction

2. Executive Summary for Celiac Disease

3. SWOT analysis of Celiac Disease

4. Celiac Disease Patient Share (%) Overview at a Glance

5. Celiac Disease Market Overview at a Glance

6. Celiac Disease Disease Background and Overview

7. Celiac Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Celiac Disease

9. Celiac Disease Current Treatment and Medical Practices

10. Celiac Disease Unmet Needs

11. Celiac Disease Emerging Therapies

12. Celiac Disease Market Outlook

13. Country-Wise Celiac Disease Market Analysis (2020–2034)

14. Celiac Disease Market Access and Reimbursement of Therapies

15. Celiac Disease Market Drivers

16. Celiac Disease Market Barriers

17. Celiac Disease Appendix

18. Celiac Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Statistics, Revenue, Prevalence, Medication, Treatment Market and Companies by DelveInsight

“Acromegaly Drugs Market”

(Albany, USA) DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Acromegaly market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acromegaly market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Acromegaly treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acromegaly market.

Request for a Free Sample Report @ Acromegaly Market Forecast

Some facts of the Acromegaly Market Report are:

• According to DelveInsight, Acromegaly market size is expected to grow at a decent CAGR by 2034.
• The Acromegaly market size was valued ~USD 1,300 million in 2023 and is to grow with a significant CAGR during the study period (2020-2034)
• Leading Acromegaly companies working in the market are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.
• Key Acromegaly Therapies expected to launch in the market are Paltusotine (CRN 00808), CAM-2029 (octreotide subcutaneous depot), and many others.
• In March 2025, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endocrine disorder characterized by consistently elevated levels of growth hormone. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP). Additionally, the EMA on February 27, 2025 granted paltusotine Orphan Drug Designation (ODD) for the treatment of acromegaly.
• In January 2025, MAR002 is a promising first-in-class antibody targeting the growth hormone receptor (GHR), being developed for the treatment of acromegaly. Acromegaly is a serious, life-threatening condition primarily driven by insulin resistance, lipotoxicity, and cardiovascular issues. Current treatments for acromegaly often fail to provide optimal disease management. In the U.S., it is estimated that over 30,000 individuals are affected by acromegaly.
• In December 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist available for adults living with acromegaly.
• In October 2024, Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly.
• On March 2024, Crinetics Pharmaceuticals announced results of a Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
• On April 2024, Camurus AB announced results of a Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
• On September 2023, Pfizer announced results of a non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
• The Acromegaly market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.
• In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.
• In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.
• In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.
• In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.
• In September 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today revealed that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist being developed for the proposed treatment and long-term maintenance therapy of acromegaly.
• In July 2024, Swedish pharmaceutical company Camurus announced positive outcomes from the Phase III ACROINNOVA 2 study, which evaluated the efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with acromegaly.
• In 2023, the total acromegaly market size in the United States was approximately USD 700 million.
• In 2023, somatostatin therapies generated the largest market size among all acromegaly treatments in the United States, reaching around USD 500 million, followed by growth hormone antagonists at approximately USD 160 million.
• In 2023, somatostatin therapies generated the highest revenue among all treatments in the EU4 and the UK, totaling approximately USD 300 million, followed by growth hormone antagonists at around USD 90 million.
• In the EU4 countries and the UK, the UK accounted for the largest share of the acromegaly market, contributing around 30% of the total market size in these regions.

Acromegaly Overview

Acromegaly is a rare hormonal disorder that results from the excessive production of growth hormone (GH), typically caused by a benign tumor on the pituitary gland known as a pituitary adenoma. This overproduction of GH leads to increased levels of insulin-like growth factor 1 (IGF-1), which causes abnormal growth of bones and tissues over time. Acromegaly usually develops gradually and often goes undiagnosed for years due to its slow progression.

Common symptoms of acromegaly include enlarged hands and feet, facial changes (such as protruding jaw and enlarged nose), joint pain, thickened skin, fatigue, and excessive sweating. If left untreated, acromegaly can lead to serious complications like hypertension, type 2 diabetes, cardiomyopathy, sleep apnea, and an increased risk of colon polyps or cancer.

Acromegaly Diagnosis involves measuring GH and IGF-1 levels in the blood, along with MRI scans to detect pituitary tumors. Acromegaly Treatment options include surgical removal of the tumor, medications to reduce GH production (such as somatostatin analogs or GH receptor antagonists), and radiation therapy when surgery isn’t feasible.

Early diagnosis and management of acromegaly are essential to prevent complications, improve quality of life, and reduce mortality risk associated with the disease.

Do you know what will be the Acromegaly market share in 7MM by 2034 @ Acromegaly Treatment Market

Acromegaly Market

The Acromegaly market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acromegaly market trends by analyzing the impact of current Acromegaly therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Acromegaly market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acromegaly market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Acromegaly market in 7MM is expected to witness a major change in the study period 2020-2034.

Acromegaly Epidemiology

The Acromegaly epidemiology section provides insights into the historical and current Acromegaly patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acromegaly market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acromegaly diagnosed prevalence pool? Download report @ Acromegaly Prevalence

Acromegaly Drugs Uptake

This section focuses on the uptake rate of the potential Acromegaly drugs recently launched in the Acromegaly market or expected to be launched in 2020-2034. The analysis covers the Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acromegaly Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acromegaly market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acromegaly Pipeline Development Activities

The Acromegaly report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acromegaly companies involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acromegaly market share by 2034? Click here @ Acromegaly Therapeutics Market

Acromegaly Therapeutics Assessment

Major key companies are working proactively in the Acromegaly Therapeutics market to develop novel therapies which will drive the Acromegaly treatment markets in the upcoming years are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.

Do you know how Paltusotine (CRN 00808) and CAM-2029 market launch will be impacting the Acromegaly market CAGR? Download sample report @ Acromegaly Drugs Market

Acromegaly Report Key Insights

1. Acromegaly Patient Population

2. Acromegaly Market Size and Trends

3. Key Cross Competition in the Acromegaly Market

4. Acromegaly Market Dynamics (Key Drivers and Barriers)

5. Acromegaly Market Opportunities

6. Acromegaly Therapeutic Approaches

7. Acromegaly Pipeline Analysis

8. Acromegaly Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acromegaly Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acromegaly Competitive Intelligence Analysis

4. Acromegaly Market Overview at a Glance

5. Acromegaly Disease Background and Overview

6. Acromegaly Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Acromegaly Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly Seven Major Market Analysis

14. Attribute Analysis

15. Acromegaly Market Outlook (7 major markets)

16. Acromegaly Access and Reimbursement Overview

17. KOL Views on the Acromegaly Market

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acromegaly Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Medication, Therapies, Treatment Market and Companies by DelveInsight

“Ulcerative Colitis Drugs Market”

(Albany, USA) DelveInsight’s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2020 to 2034 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

The Ulcerative Colitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Ulcerative Colitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Ulcerative Colitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Ulcerative Colitis market.

To know more in detail about Ulcerative Colitis Market report offerings, click here @ Ulcerative Colitis Market Forecast

Key highlights from the Ulcerative Colitis Market Insight report

• According to DelveInsight, the Ulcerative Colitis market size is expected to grow at a decent CAGR by 2034.
• The total Ulcerative Colitis Market Size in the 7MM was approximately USD 8090 million in 2022 and is projected to increase during the forecast period (2023–2034).
• In the United States, the total number of diagnosed prevalent cases of ulcerative colitis was 1,437,600 in 2022.
• Leading Ulcerative Colitis companies working proactively in the therapeutic market are Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
• The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.
• According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
• In March 2025, Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an update on its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC).
• In February 2025, Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC).
• In January 2025, Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced a significant milestone in the Phase 3 ABTECT clinical trial evaluating obefazimod for the treatment of moderately to severely active UC.
• In September 2024, Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including UC.
• In August 2024, Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that in July 2024, the 600th participant was enrolled in the Phase 3 ABTECT Trial. Based on this milestone and current enrollment pace, the Company reaffirms expectations to reach full enrollment in early Q1 2025.
• On April 2024, Vedanta Biosciences announced results of A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.
• On March 2024, Eli Lilly announced results of a Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship with Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab.

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Ulcerative Colitis Overview

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the colon and rectum. It is an autoimmune condition in which the immune system mistakenly attacks the intestinal lining, leading to symptoms such as abdominal pain, persistent diarrhea, rectal bleeding, weight loss, and fatigue. The severity of symptoms varies, with periods of flare-ups and remission.

The exact cause of ulcerative colitis is unknown, but genetic factors, immune system dysfunction, and environmental triggers are believed to play a role. It is commonly diagnosed in young adults between 15 and 30 years old. Diagnosis involves clinical evaluation, blood tests, stool tests, colonoscopy, and imaging studies.

Treatment focuses on reducing inflammation and managing symptoms. Mild to moderate cases are treated with aminosalicylates (5-ASA drugs) like mesalamine, while corticosteroids, immunosuppressants, and biologic therapies (such as TNF inhibitors and JAK inhibitors) are used for more severe cases. In refractory cases or complications like toxic megacolon, surgery (colectomy) may be required.

While ulcerative colitis has no cure, early diagnosis and proper treatment can improve quality of life. Ongoing research into new biologics and microbiome-based therapies offers hope for better disease management.

Ulcerative Colitis Epidemiology Segmentation

DelveInsight’s analysts indicate that the total diagnosed cases of Ulcerative Colitis in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2034, during the forecast period.

The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

• Total Prevalent Ulcerative Colitis Cases
• Total Diagnosed Prevalent Ulcerative Colitis Cases
• Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Total Treated Ulcerative Colitis Cases

Download Ulcerative Colitis Market sample to know more about the epidemiology and market trends @ Ulcerative colitis Prevalence

Ulcerative Colitis Pipeline Therapies and Key Companies

• Jyseleca (filgotinib): Gilead Sciences/Galapagos NV
• Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie
• Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
• Mirikizumab (LY-3074828): Eli Lilly and Company
• Etrasimod: Arena Pharmaceuticals
• Tremfya (Guselkumab): Janssen (Johnson & Johnson)
• Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson
• BT-11: Landos Biopharma

Ulcerative Colitis Market Dynamics

The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.

A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ Ulcerative colitis Medication and Companies

Scope of the Ulcerative Colitis Market Report

• Study Period: 2020-34
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma
• Key Ulcerative Colitis Drugs: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and barriers
• Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs
• KOL views
• Reimbursement Scenario

Download Market sample to know more about the recent happenings in the Ulcerative colitis therapeutic landscape @ Ulcerative colitis Clinical Trials and Advancements

Table of Contents

1. Key Insights

2. Report Introduction of Ulcerative Colitis

3. Ulcerative Colitis Market Overview at a Glance

4. Executive Summary of Ulcerative Colitis

5. Ulcerative Colitis Epidemiology and Market Forecast Flow

6. Ulcerative Colitis: Disease Background and Overview

7. Ulcerative Colitis Diagnosis

8. Ulcerative Colitis Current Treatment

9. Ulcerative Colitis Epidemiology and Patient Population

10. Ulcerative Colitis Patient Journey

11. Key Endpoints in Ulcerative Colitis Clinical Trials

12. Ulcerative Colitis Marketed Therapies of Ulcerative Colitis

13. Ulcerative Colitis Emerging Therapies

14. Conjoint Analysis of Ulcerative Colitis

15. Ulcerative Colitis: Seven Major Market Analysis

16. The United States Market Size

17. Ulcerative Colitis Market Access and Reimbursement

18. Ulcerative Colitis Market Drivers

19. Ulcerative Colitis Market Barriers

20. Ulcerative Colitis SWOT Analysis

21. Ulcerative Colitis Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight

“Spinal Muscular Atrophy Pipeline”

(Albany, USA) “Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: Spinal Muscular Atrophy Clinical Trials and Pipeline

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

• In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA
• Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
• Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment
• Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
• In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
• In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®).
• On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
• On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
• On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children’s Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C).
• On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®).
• On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
• On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study.
• On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA)

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: Spinal Muscular Atrophy Drugs and Therapies

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression.

Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening.

Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life.

Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA.

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

• Spinal Muscular Atrophy Assessment by Product Type
• Spinal Muscular Atrophy By Stage and Product Type
• Spinal Muscular Atrophy Assessment by Route of Administration
• Spinal Muscular Atrophy By Stage and Route of Administration
• Spinal Muscular Atrophy Assessment by Molecule Type
• Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

• ACTX-401: Novartis
• Apitegromab: Scholar Rock
• GYM329: Roche
• And Many Others

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment- Spinal Muscular Atrophy Medication

Spinal Muscular Atrophy Pipeline Analysis:

• The Spinal Muscular Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
• Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
• The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

• Coverage: Global
• Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others
• Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
• Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
• Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Request for Sample Report @ Spinal Muscular Atrophy Pipeline Outlook

Table of Contents

• Spinal Muscular Atrophy Report Introduction
• Spinal Muscular Atrophy Executive Summary
• Spinal Muscular Atrophy Overview
• Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
• Spinal Muscular Atrophy Pipeline Therapeutics
• Spinal Muscular Atrophy Late Stage Products (Phase II/III)
• Spinal Muscular Atrophy Mid Stage Products (Phase II)
• Spinal Muscular Atrophy Early Stage Products (Phase I)
• Spinal Muscular Atrophy Preclinical Stage Products
• Spinal Muscular Atrophy Therapeutics Assessment
• Spinal Muscular Atrophy Inactive Products
• Company-University Collaborations (Licensing/Partnering) Analysis
• Spinal Muscular Atrophy Key Companies
• Spinal Muscular Atrophy Key Products
• Spinal Muscular Atrophy Unmet Needs
• Spinal Muscular Atrophy Market Drivers and Barriers
• Spinal Muscular Atrophy Future Perspectives and Conclusion
• Spinal Muscular Atrophy Analyst Views
• Appendix
• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline Drugs Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

“Traumatic Brain Injury Market”

(Albany, USA) DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Traumatic Brain Injury, offering comprehensive insights into the Traumatic Brain Injury revenue trends, prevalence, and treatment landscape. The report delves into key Traumatic Brain Injury statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Traumatic Brain Injury therapies. Additionally, we cover the landscape of Traumatic Brain Injury clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Traumatic Brain Injury treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Traumatic Brain Injury space.

To Know in detail about the Traumatic Brain Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Traumatic Brain Injury Market Forecast

Some of the key facts of the Traumatic Brain Injury Market Report:

• The Traumatic Brain Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The total market size for TBI in the US was approximately USD 5 billion in 2023. DelveInsight’s analysis forecasts market growth driven by the introduction of new therapies. As a result, the market size is expected to expand during the study period from 2020 to 2034.
• DelveInsight’s analysts estimate that the total market size for TBI in the EU4 and the UK was approximately USD 900 million in 2023, with expectations for further growth during the forecast period from 2024 to 2034.
• The market size for TBI in Japan was around USD 380 million in 2023, representing 6% of the total market across the 7MM, and is projected to increase by 2034.
• Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
• Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
• The Traumatic Brain Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Traumatic Brain Injury pipeline products will significantly revolutionize the Traumatic Brain Injury market dynamics.
• According to DelveInsight’s analysis, the total number of incident cases of Traumatic Brain Injury (TBI) in the 7MM was approximately 4,254 thousand in 2023 and is expected to increase at a significant compound annual growth rate (CAGR) throughout the forecast period from 2024 to 2034.
• Among the EU4 and UK countries, Germany reported the highest number of incident cases of Traumatic Brain Injury (TBI) in 2023, with 238 thousand cases, while Spain had the lowest at 134 thousand cases. The number of cases is anticipated to increase in the EU4 and the UK.
• The estimates indicate that the incident population of Traumatic Brain Injury (TBI) in Japan is projected to be 325 thousand cases in 2023, but this number is expected to decline by 2034.
• In 2023, 66% of males and 34% of females in the 7MM experienced Traumatic Brain Injury (TBI). These cases are expected to increase during the forecast period from 2024 to 2034.
• In February 2025, Merz Pharmaceuticals GmbH announced results of a Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment
• In January 2025, Hope Biosciences announced results of a study to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury and/or hypoxic-ischemic encephalopathy in adults.
• In October 2023, Abalonex, LLC announced results of a Parallel Group Treatment, Phase 2A, Double-blind, 3-arm Study to Investigate Safety and Efficacy of ABX-101 Compared With Placebo in Male and Female Participants, Aged 18 to 50 Years, With Moderate-to-severe Traumatic Brain Injury

Traumatic Brain Injury Overview

Traumatic Brain Injury is a serious medical condition caused by a sudden impact, blow, or jolt to the head, leading to brain dysfunction. Traumatic Brain Injury can range from mild concussions to severe brain damage, affecting cognitive, physical, and emotional functions. The primary causes of Traumatic Brain Injury include falls, motor vehicle accidents, sports injuries, and violent assaults.

Traumatic Brain Injury symptoms vary based on severity and may include headaches, dizziness, memory loss, confusion, mood changes, and loss of consciousness. In severe cases, Traumatic Brain Injury can result in long-term disability, coma, or even death. Diagnosis of Traumatic Brain Injury involves neurological examinations, imaging tests such as CT scans and MRI, and cognitive assessments.

Treatment for Traumatic Brain Injury depends on the severity and includes rest, medications, rehabilitation therapies, and in critical cases, surgical interventions. Ongoing research in Traumatic Brain Injury focuses on neuroprotective drugs, stem cell therapy, and advanced rehabilitation techniques to enhance recovery.

The increasing prevalence of Traumatic Brain Injury has driven advancements in prevention strategies, including protective gear, public safety awareness, and early intervention. As medical research progresses, new therapeutic approaches for Traumatic Brain Injury continue to emerge, improving patient outcomes and quality of life.

Get a Free sample for the Traumatic Brain Injury Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Traumatic Brain Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Traumatic Brain Injury Epidemiology Segmentation:

The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Traumatic Brain Injury
• Prevalent Cases of Traumatic Brain Injury by severity
• Gender-specific Prevalence of Traumatic Brain Injury
• Diagnosed Cases of Episodic and Chronic Traumatic Brain Injury

Download the report to understand which factors are driving Traumatic Brain Injury epidemiology trends @ Traumatic Brain Injury Epidemiology Forecast

Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Traumatic Brain Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Traumatic Brain Injury Therapies and Key Companies

• Ronopterin (VAS203): VeriNOS Pharmaceuticals GmbH
• CEVA101: Cellvation, Inc.
• ABX-101: Abalonex, LLC
• SB623 (vandefitemcel): The SanBio Group
• Autologous HB-adMSCs: Hope Biosciences
• [F-18]Flornaptitril: CereMark Pharma, LLC
• ABX-101: Abalonex, LLC
• Propranolol: Hamad Medical Corporation
• MYOBLOC: Supernus Pharmaceuticals, Inc.
• NT 201: Merz Pharmaceuticals GmbH

Discover more about therapies set to grab major Traumatic Brain Injury market share @ Traumatic Brain Injury Treatment Landscape

Traumatic Brain Injury Market Strengths

• Traumatic Brain Injury is a significant global health issue, with a growing number of cases due to a rising number of head injuries and increasing awareness.
• Advances in medical technology have led to better diagnosis, treatment, and management options for Traumatic Brain Injury, including neuroimaging techniques and neuroprotective drugs.

Traumatic Brain Injury Market Opportunities

• The therapeutic market of Traumatic Brain Injury is very scarce, creating an opportunity for key market players to enter the Traumatic Brain Injury market.
• The trend toward precision medicine opens avenues for developing targeted treatments, allowing for more effective and personalized interventions in Traumatic Brain Injury management.

Scope of the Traumatic Brain Injury Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
• Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
• Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
• Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Traumatic Brain Injury Unmet Needs, KOL’s views, Analyst’s views, Traumatic Brain Injury Market Access and Reimbursement

To know more about Traumatic Brain Injury companies working in the treatment market, visit @ Traumatic Brain Injury Clinical Trials and Therapeutic Assessment

Table of Contents

1. Traumatic Brain Injury Market Report Introduction

2. Executive Summary for Traumatic Brain Injury

3. SWOT analysis of Traumatic Brain Injury

4. Traumatic Brain Injury Patient Share (%) Overview at a Glance

5. Traumatic Brain Injury Market Overview at a Glance

6. Traumatic Brain Injury Disease Background and Overview

7. Traumatic Brain Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Traumatic Brain Injury

9. Traumatic Brain Injury Current Treatment and Medical Practices

10. Traumatic Brain Injury Unmet Needs

11. Traumatic Brain Injury Emerging Therapies

12. Traumatic Brain Injury Market Outlook

13. Country-Wise Traumatic Brain Injury Market Analysis (2020–2034)

14. Traumatic Brain Injury Market Access and Reimbursement of Therapies

15. Traumatic Brain Injury Market Drivers

16. Traumatic Brain Injury Market Barriers

17. Traumatic Brain Injury Appendix

18. Traumatic Brain Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/partner-identification-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traumatic Brain Injury Market Analysis 2034: EMA, PDMA, FDA Approval, Medication, Clinical Trials, Epidemiology, Therapies, Statistics, Revenue, Treatment Market and Companies by DelveInsight

“Obesity Drugs Market”

(Albany, USA) DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market.

Request for a Free Sample Report @ Obesity Market Forecast

Some facts of the Obesity Market Report are:

• In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk’s efforts to meet the needs of individuals living with obesity, following the FDA’s confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand.
• In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance.
• In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company’s early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action.
• In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly’s rival GLP-1 drug Zepbound may still have an advantage over Wegovy.
• In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.
• In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly’s reply due by January 21.
• As per DelveInsight’s estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023.
• DelveInsight’s consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023.
• According to the findings, treatment rate for children was found to be less than that of adults across countries.
• Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany.
• The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
• Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others.
• On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly’s investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration.
• On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments.
• On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity.

Obesity Overview

Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens.

Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market

Obesity Market

The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034.

Obesity Epidemiology

The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Obesity Epidemiology @ Obesity Market Dynamics

Obesity Drugs Uptake

This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obesity Pipeline Development Activities

The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs

Obesity Therapeutics Assessment

Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others.

Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements

Obesity Report Key Insights

1. Obesity Patient Population

2. Obesity Market Size and Trends

3. Key Cross Competition in the Obesity Market

4. Obesity Market Dynamics (Key Drivers and Barriers)

5. Obesity Market Opportunities

6. Obesity Therapeutic Approaches

7. Obesity Pipeline Analysis

8. Obesity Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Obesity Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Obesity Competitive Intelligence Analysis

4. Obesity Market Overview at a Glance

5. Obesity Disease Background and Overview

6. Obesity Patient Journey

7. Obesity Epidemiology and Patient Population

8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices

9. Obesity Unmet Needs

10. Key Endpoints of Obesity Treatment

11. Obesity Marketed Products

12. Obesity Emerging Therapies

13. Obesity Seven Major Market Analysis

14. Attribute Analysis

15. Obesity Market Outlook (7 major markets)

16. Obesity Access and Reimbursement Overview

17. KOL Views on the Obesity Market

18. Obesity Market Drivers

19. Obesity Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight